Given the striking molecular heterogeneity that permeates all aspects of DLBCL biology, understanding heterogeneity in NF-κB signaling may unlock pathway- and subunit-specific therapeutic approaches. Here, NFKB1 is linked to diffuse large B-cell lymphoma.